It looks like this abstract may be the reason for the 10% drop in NKTR stock today.
https://meetinglibrary.asco.org/record/169673/abstract
It shows updated results from the PIVOT-02 trial of NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC).
Way too technical for me to get much of use out of it, other than the summary that says there was a 48 percent overall response rate compared to a 60 percent response rate reported in June. The company will present detailed results at the symposium Feb. 15.
If any others that are still following NKTR can get any more out of this release, please do!